Results 1 to 10 of about 231,349 (305)

Systematic Review of the Safety of Immune Checkpoint Inhibitors Among Kidney Transplant Patients

Kidney International Reports, 2020
Introduction: Kidney transplant (Ktx) recipients are excluded from clinical trials of immune checkpoint inhibitors. The aim of this systematic review was to assess the safety of immune checkpoint inhibitors among Ktx patients.
Sandhya Manohar, Charat Thongprayoon, Wisit Cheungpasitporn, Svetomir N. Markovic, Sandra M. Herrmann   +4 more
doaj   +3 more sources

Gut microbiome on immune checkpoint inhibitor therapy and consequent immune-related colitis: a review [PDF]

Intestinal Research, 2023
Immune checkpoint inhibitors have dramatically revolutionized the therapeutic landscape for patients with advanced malignancies. Recently, convincing evidence has shown meaningful influence of gut microbiome on human immune system.
Sung Wook Hwang, Min Kyu Kim, Mi-Na Kweon   +2 more
doaj   +1 more source

Overcoming resistance to immune checkpoint inhibitors in hepatocellular carcinoma: Challenges and opportunities

Frontiers in Oncology, 2022
Hepatocellular carcinoma is one of the leading causes of cancer mortality globally, and its incidence is increasing. Immune checkpoint therapy has revolutionized the treatment of hepatocellular carcinoma over the past few years.
Qingqing Xie, Pengfei Zhang, Yuanyuan Wang, Wuxuan Mei, Changchun Zeng   +4 more
doaj   +1 more source

Nano-Chemotherapy synergize with immune checkpoint inhibitor- A better option?

Frontiers in Immunology, 2022
Immune checkpoint inhibitor (ICI) is one of the most important tumor treatment methods. Although the therapeutic efficiency of immune checkpoint inhibitor mono-therapy is limited, the combination of chemotherapy plus immune checkpoint inhibitors has ...
Xinye Qian, Xinye Qian, Wang Hu, Wang Hu, Jun Yan, Jun Yan   +5 more
doaj   +1 more source

Research Advances in Intracranial Radiotherapy Combined with Immune Checkpoint Inhibitors on Lung Cancer Brain Metastasis

Zhongliu Fangzhi Yanjiu, 2020
In recent years, immunotherapy has been continuously developed, and the safety and efficacy of immune checkpoint inhibitors combined with intracranial radiotherapy for melanoma brain metastasis have been initially recognized.
HE Qian, REN Qinglan
doaj   +1 more source

Research Progress on Cardiotoxicity of PD-1/PD-L1 Immune Checkpoint Inhibitors

Zhongliu Fangzhi Yanjiu, 2021
Cardiotoxicity is a serious complication of antineoplastic drugs. With the continuous development of antineoplastic drugs, immune checkpoint inhibitors have been used in the treatment of a variety of cancers.
YU Lin, LI Guangping, ZHOU Changyu, FU Huaying   +3 more
doaj   +1 more source

Response to targeted therapy or chemotherapy following immunotherapy in patients with gastrointestinal cancers - a case series

Journal for ImmunoTherapy of Cancer, 2019
Background In non-small cell lung cancer, response rates to chemotherapy given after immune checkpoint inhibitors has been reported to be higher compared to response rates to chemotherapy given before immune checkpoint inhibitors.
Rayan Alsuwaigh, Joycelyn Lee, Gloria Chan, Cheng Ean Chee, Su Pin Choo   +4 more
doaj   +1 more source

Immune Checkpoint Inhibitor-Induced Central Diabetes Insipidus: Looking for the Needle in the Haystack or a Very Rare Side-Effect to Promptly Diagnose?

Frontiers in Oncology, 2022
Immune checkpoint inhibitors have improved the survival in patients affected by an increasing number of malignancies, but they may also trigger various autoimmune side-effects, including endocrinopathies.
Agnese Barnabei, Lidia Strigari, Andrea Corsello, Rosa Maria Paragliola, Luca Falzone, Roberto Salvatori, Salvatore Maria Corsello, Salvatore Maria Corsello, Francesco Torino   +8 more
doaj   +1 more source

Challenges of Immune Checkpoint Inhibitors in Treatment of Non-small Cell Lung Cancer

Zhongliu Fangzhi Yanjiu, 2019
With the gradually in-depth research of immune checkpoint, the checkpoint inhibitors, such as programmed death-1(PD-1) inhibitors, programmed death–ligand 1(PD-L1) inhibitors and cytotoxic T lymphocyte-associated protein-4(CTLA-4) inhibitors, had made ...
LI Xiangmin, FAN Zaiwen
doaj   +1 more source

Immune checkpoint inhibitor-associated acute kidney injury and mortality: An observational study.

PLoS ONE, 2021
BackgroundImmune checkpoint inhibitors, approved for the treatment of various types of cancer, are known to cause a unique spectrum of side effects, including acute kidney injury (AKI).
Marije S Koks, Gurbey Ocak, Britt B M Suelmann, Cornelia A R Hulsbergen-Veelken, Saskia Haitjema, Marieke E Vianen, Marianne C Verhaar, Karin A H Kaasjager, Meriem Khairoun   +8 more
doaj   +1 more source